Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical […]
Month: May 2025
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical […]
Bitget affirme son leadership mondial et son engagement communautaire au TOKEN2049 Dubaï
DUBAÏ, Émirats arabes unis, 06 mai 2025 (GLOBE NEWSWIRE) — Bitget, première bourse de cryptomonnaies et société Web3, a clôturé une semaine marquante et enrichissante au TOKEN2049. En tant que sponsor Gold de l’événement, Bitget a affiché sa présence par une participation de premier plan, un dialogue stratégique et des activités communautaires qui lui ont permis d’échanger […]
Antalpha Announces Launch of Initial Public Offering
SINGAPORE, May 06, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (“Antalpha” or the “Company”) today announced that it has launched the roadshow for its proposed initial public offering of 3,850,000 ordinary shares with expected pricing between $11.00 and $13.00 per ordinary share. Antalpha expects to grant the underwriters a 30-day option to purchase an […]
Antalpha Announces Launch of Initial Public Offering
SINGAPORE, May 06, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (“Antalpha” or the “Company”) today announced that it has launched the roadshow for its proposed initial public offering of 3,850,000 ordinary shares with expected pricing between $11.00 and $13.00 per ordinary share. Antalpha expects to grant the underwriters a 30-day option to purchase an […]